menopause and tirzepatide Unlocking the potential of hormone therapy! This study explores how it influences tirzepatide-induced weight loss in postmenopausal women with obesity. Discover the promising results that could reshape approaches to weight management The 5% Problem: The Access

In a Lilly-funded trial published by The Lancet, patients with type 2 diabetes who took 12 to 36 milligrams of orforglipron lost an average of 15 to 20 pounds, compared with 8 to 11 pounds for those taking 7 to 14 milligrams of Rybelsus

Reputable bodies such as the Endocrine Society and the American Diabetes Association stress careful patient selection and monitoring [5]

Philippe, Genve (Diabtologie)

Many who use a GLP-1 prescription over several months experience weight loss, stabilized blood sugar levels, better sleep health, more energy, happier mood, and better health outcomes

Adverse events include data previously reported for the 20-week trial